BACKGROUND: The authors are conducting clinical trials of the HER-2/neu E75-peptide vaccine in clinically disease-free breast cancer (BC) patients. Their phase 1-2 trials revealed that the E75 + granulocyte-macrophage colony-stimulating factor (GM-CSF) vaccine is safe and effective in stimulating clonal expansion of E75-specific CD8(+) T cells. They assessed the need for and response to a booster after completion of primary vaccination series. METHODS: BC patients enrolled in the E75 vaccine trials who were ≥6 months from completion of their primary vaccination series were offered boosters with E75 + GM-CSF. Patients were monitored for toxicity. E75-specific CD8(+) T cells were quantified using the human leukocyte antigen-A2:immunoglobulin G dimer before and after boosting. RESULTS: Fifty-three patients received the vaccine booster. Median time from primary vaccination series was 9 months (range, 6-35 months), and median residual E75-specific immunity was 0.70% (range, 0-3.49%) CD8(+) lymphocytes. Elevated residual immunity (ERI) (CD8(+) E75-specific T cells >0.5%) was seen in 94.4% of patients at 6 months from primary vaccination series versus 48% of patients at >6 months (P = .002). The booster was well tolerated, with only grade 1 and 2 toxicity observed. Local reactions were more robust in patients receiving the booster at 6 months from primary vaccination series compared with those at >6 months (99.4 ± 6.1 mm vs 81.8 ± 4.1 mm, P = .01). In patients lacking ERI, 85% had increased ERI after vaccination (P = .0014). CONCLUSIONS: The HER-2/neu E75 peptide vaccine E75 stimulates specific immunity in disease-free BC patients. However, immunity wanes with time. A vaccine booster is safe and effective in stimulating E75-specific immunity in those patients without ERI. These results suggest that the booster may be most effective at 6 months after completion of the primary vaccination series. Published 2010 American Cancer Society.
BACKGROUND: The authors are conducting clinical trials of the HER-2/neu E75-peptide vaccine in clinically disease-free breast cancer (BC) patients. Their phase 1-2 trials revealed that the E75 + granulocyte-macrophage colony-stimulating factor (GM-CSF) vaccine is safe and effective in stimulating clonal expansion of E75-specific CD8(+) T cells. They assessed the need for and response to a booster after completion of primary vaccination series. METHODS: BC patients enrolled in the E75 vaccine trials who were ≥6 months from completion of their primary vaccination series were offered boosters with E75 + GM-CSF. Patients were monitored for toxicity. E75-specific CD8(+) T cells were quantified using the human leukocyte antigen-A2:immunoglobulin G dimer before and after boosting. RESULTS: Fifty-three patients received the vaccine booster. Median time from primary vaccination series was 9 months (range, 6-35 months), and median residual E75-specific immunity was 0.70% (range, 0-3.49%) CD8(+) lymphocytes. Elevated residual immunity (ERI) (CD8(+) E75-specific T cells >0.5%) was seen in 94.4% of patients at 6 months from primary vaccination series versus 48% of patients at >6 months (P = .002). The booster was well tolerated, with only grade 1 and 2 toxicity observed. Local reactions were more robust in patients receiving the booster at 6 months from primary vaccination series compared with those at >6 months (99.4 ± 6.1 mm vs 81.8 ± 4.1 mm, P = .01). In patients lacking ERI, 85% had increased ERI after vaccination (P = .0014). CONCLUSIONS: The HER-2/neu E75 peptide vaccine E75 stimulates specific immunity in disease-free BC patients. However, immunity wanes with time. A vaccine booster is safe and effective in stimulating E75-specific immunity in those patients without ERI. These results suggest that the booster may be most effective at 6 months after completion of the primary vaccination series. Published 2010 American Cancer Society.
Authors: Elizabeth A Mittendorf; Guy T Clifton; Jarrod P Holmes; Kevin S Clive; Ritesh Patil; Linda C Benavides; Jeremy D Gates; Alan K Sears; Alexander Stojadinovic; Sathibalan Ponniah; George E Peoples Journal: Cancer Date: 2011-10-11 Impact factor: 6.860
Authors: Timothy J Vreeland; Jennifer K Litton; Na Qiao; Anne V Philips; Gheath Alatrash; Diane F Hale; Doreen O Jackson; Kaitlin M Peace; Julia M Greene; John S Berry; Guy T Clifton; George E Peoples; Elizabeth A Mittendorf Journal: Clin Immunol Date: 2018-03-21 Impact factor: 3.969
Authors: E A Mittendorf; G T Clifton; J P Holmes; E Schneble; D van Echo; S Ponniah; G E Peoples Journal: Ann Oncol Date: 2014-06-06 Impact factor: 32.976
Authors: Keith L Knutson; Matthew S Block; Nadine Norton; Courtney L Erskine; Timothy J Hobday; Allan B Dietz; Douglas Padley; Michael P Gustafson; Danell Puglisi-Knutson; Toni Kay Mangskau; Saranya Chumsri; Amylou C Dueck; Lavakumar Karyampudi; Glynn Wilson; Amy C Degnim Journal: Clin Cancer Res Date: 2019-11-22 Impact factor: 12.531
Authors: Elizabeth A Mittendorf; Alexandros Ardavanis; Jennifer K Litton; Nathan M Shumway; Diane F Hale; James L Murray; Sonia A Perez; Sathibalan Ponniah; Constantin N Baxevanis; Michael Papamichail; George E Peoples Journal: Oncotarget Date: 2016-10-04